A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 2, 2015, Pages 373-380

  Suzuki, Kazuhiro ^a   Ozono, Seiichiro ^b   Yamaguchi, Akito ^c   Koike, Hidekazu ^a   Matsui, Hiroshi ^a   Nagata, Masao ^b   Takubo, Takatoshi ^d   Miyashita, Kana ^d   Matsushima, Takafumi ^d   Akaza, Hideyuki ^e  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HARASANSHIN HOSPITAL   (Japan)

^d TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

17,20 Lyase inhibitor; Castration resistant prostate cancer; Orteronel; Phase 1

Indexed keywords

MINERALOCORTICOID; ORTERONEL; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANDROGEN; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ABDOMINAL DISCOMFORT; ACUTE PANCREATITIS; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DRUG EXCRETION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERAMYLASEMIA; HYPERTENSION; HYPOKALEMIA; JAPANESE (PEOPLE); MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URINARY EXCRETION; BLOOD; CLINICAL TRIAL; JAPAN; MIDDLE AGED; MULTICENTER STUDY; ORCHIECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

AGED; ANDROGENS; ANTINEOPLASTIC AGENTS; HUMANS; IMIDAZOLES; JAPAN; MALE; MIDDLE AGED; NAPHTHALENES; ORCHIECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84924987643     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2654-y     Document Type: Article

References (17)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61:1079-1092
2. Hotte SJ, Saad F (2010) Current management of castrate-resistant prostate cancer. Curr Oncol 17(suppl 2):S72-S79
3. Cai C, Balk SP (2011) Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 18:R175-R182
4. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407-6415
5. Ang JE, Olmos D, de Bono JS (2009) CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 100:671-675
6. Schweizer MT, Antonarakis ES (2012) Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol 4:167-178
7. Kaku T, Hitaka T, Ojida A, Matsunaga N, Adachi M, Tanaka T, Hara T, Yamaoka M, Kusaka M, Okuda T, Asahi S, Furuya S, Tasaka A (2011) Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 19:6383-6399
8. Payne AH, Hales DB (2004) Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 25:947-970
9. Vasaitis TS, Bruno RD, Njar VC (2011) CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 125:23-31
10. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005
11. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148
12. Attard G, Reid AHM, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742-3748
13. Yamaoka M, Hara T, Hitaka T, Kaku T, Takeuchi T, Takahashi J, Asahi S, Miki H, Tasaka A, Kusaka M (2012) Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol 129:115-128
14. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26:1148-1159
15. Andoh M, Fujiwara Y, Shimada Y (2006) The revision of guidelines for clinical evaluation methods of anti-cancer drugs in Japan. Gan To Kagaku Ryoho 33:1015-1019 (Article in Japanese; English abstract)
16. Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, Mukai H, Tahara M, Nakajima H, Nakajima K (2008) Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99:1492-1498
17. Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12:1665-1671